
Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Analysis and Forecast 2025-2031
Description
Summary
According to APO Research, The global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs include Allergan, Amneal Pharms, Astellas Pharmaceuticals, Bausch Health, Sebela Pharmaceuticals and Pharscin Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales, projected growth trends, production technology, application and end-user industry.
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Company
Allergan
Amneal Pharms
Astellas Pharmaceuticals
Bausch Health
Sebela Pharmaceuticals
Pharscin Pharma
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Type
XIFAXAN
Lotronex
Viberzi
Other
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Application
Hospitals Pharmacy
Retail Pharmacy
Other
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
According to APO Research, The global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs include Allergan, Amneal Pharms, Astellas Pharmaceuticals, Bausch Health, Sebela Pharmaceuticals and Pharscin Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales, projected growth trends, production technology, application and end-user industry.
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Company
Allergan
Amneal Pharms
Astellas Pharmaceuticals
Bausch Health
Sebela Pharmaceuticals
Pharscin Pharma
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Type
XIFAXAN
Lotronex
Viberzi
Other
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Application
Hospitals Pharmacy
Retail Pharmacy
Other
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
Table of Contents
192 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Type
- 1.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Type, 2020 VS 2024 VS 2031
- 1.2.2 XIFAXAN
- 1.2.3 Lotronex
- 1.2.4 Viberzi
- 1.2.5 Other
- 1.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Application
- 1.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Application, 2020 VS 2024 VS 2031
- 1.3.2 Hospitals Pharmacy
- 1.3.3 Retail Pharmacy
- 1.3.4 Other
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
- 2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Dynamics
- 2.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Trends
- 2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Drivers
- 2.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Opportunities and Challenges
- 2.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Restraints
- 3 Global Market Growth Prospects
- 3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Estimates and Forecasts (2020-2031)
- 3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region
- 3.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region: 2020 VS 2024 VS 2031
- 3.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2020-2025)
- 3.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2026-2031)
- 3.2.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2020-2031)
- 3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Estimates and Forecasts 2020-2031
- 3.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region
- 3.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region: 2020 VS 2024 VS 2031
- 3.4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2020-2025)
- 3.4.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2026-2031)
- 3.4.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2020-2031)
- 3.5 US & Canada & Mexico
- 3.6 Europe
- 3.7 China
- 3.8 Asia (Excluding China)
- 3.9 South America, Middle East and Africa
- 4 Market Competitive Landscape by Manufacturers
- 4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Manufacturers
- 4.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Manufacturers (2020-2025)
- 4.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Manufacturers (2020-2025)
- 4.1.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2024
- 4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Manufacturers
- 4.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Manufacturers (2020-2025)
- 4.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Manufacturers (2020-2025)
- 4.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers Sales Share Top 10 and Top 5 in 2024
- 4.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Price by Manufacturers (2020-2025)
- 4.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Manufacturers Ranking, 2023 VS 2024 VS 2025
- 4.5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 4.6 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers, Product Type & Application
- 4.7 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturers' Establishment Date
- 4.8 Market Competitive Analysis
- 4.8.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market CR5 and HHI
- 4.8.2 2024 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Tier 1, Tier 2, and Tier 3
- 5 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Type
- 5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type
- 5.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2020 VS 2024 VS 2031)
- 5.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2020-2031) & (US$ Million)
- 5.1.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2020-2031)
- 5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type
- 5.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2020 VS 2024 VS 2031)
- 5.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2020-2031) & (K Pcs)
- 5.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2020-2031)
- 5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type
- 6 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market by Application
- 6.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application
- 6.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2020 VS 2024 VS 2031)
- 6.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2020-2031) & (US$ Million)
- 6.1.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Application (2020-2031)
- 6.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application
- 6.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2020 VS 2024 VS 2031)
- 6.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2020-2031) & (K Pcs)
- 6.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2020-2031)
- 6.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Application
- 7 Company Profiles
- 7.1 Allergan
- 7.1.1 Allergan Comapny Information
- 7.1.2 Allergan Business Overview
- 7.1.3 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.1.4 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
- 7.1.5 Allergan Recent Developments
- 7.2 Amneal Pharms
- 7.2.1 Amneal Pharms Comapny Information
- 7.2.2 Amneal Pharms Business Overview
- 7.2.3 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.2.4 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
- 7.2.5 Amneal Pharms Recent Developments
- 7.3 Astellas Pharmaceuticals
- 7.3.1 Astellas Pharmaceuticals Comapny Information
- 7.3.2 Astellas Pharmaceuticals Business Overview
- 7.3.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.3.4 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
- 7.3.5 Astellas Pharmaceuticals Recent Developments
- 7.4 Bausch Health
- 7.4.1 Bausch Health Comapny Information
- 7.4.2 Bausch Health Business Overview
- 7.4.3 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.4.4 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
- 7.4.5 Bausch Health Recent Developments
- 7.5 Sebela Pharmaceuticals
- 7.5.1 Sebela Pharmaceuticals Comapny Information
- 7.5.2 Sebela Pharmaceuticals Business Overview
- 7.5.3 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.5.4 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
- 7.5.5 Sebela Pharmaceuticals Recent Developments
- 7.6 Pharscin Pharma
- 7.6.1 Pharscin Pharma Comapny Information
- 7.6.2 Pharscin Pharma Business Overview
- 7.6.3 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
- 7.6.4 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Portfolio
- 7.6.5 Pharscin Pharma Recent Developments
- 8 North America
- 8.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Type
- 8.1.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2020-2031)
- 8.1.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2020-2031)
- 8.1.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2020-2031)
- 8.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Application
- 8.2.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2020-2031)
- 8.2.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2020-2031)
- 8.2.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Application (2020-2031)
- 8.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country
- 8.3.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 8.3.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2020 VS 2024 VS 2031)
- 8.3.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Country (2020-2031)
- 8.3.4 United States
- 8.3.5 Canada
- 9 Europe
- 9.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Type
- 9.1.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2020-2031)
- 9.1.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2020-2031)
- 9.1.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2020-2031)
- 9.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Application
- 9.2.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2020-2031)
- 9.2.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2020-2031)
- 9.2.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Application (2020-2031)
- 9.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country
- 9.3.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 9.3.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2020 VS 2024 VS 2031)
- 9.3.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Country (2020-2031)
- 9.3.4 Germany
- 9.3.5 France
- 9.3.6 U.K.
- 9.3.7 Italy
- 9.3.8 Netherlands
- 9.3.9 Nordic Countries
- 10 China
- 10.1 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Type
- 10.1.1 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2020-2031)
- 10.1.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2020-2031)
- 10.1.3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2020-2031)
- 10.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Application
- 10.2.1 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2020-2031)
- 10.2.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2020-2031)
- 10.2.3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Application (2020-2031)
- 11 Asia (Excluding China)
- 11.1 Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Type
- 11.1.1 Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2020-2031)
- 11.1.2 Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2020-2031)
- 11.1.3 Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2020-2031)
- 11.2 Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Application
- 11.2.1 Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2020-2031)
- 11.2.2 Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2020-2031)
- 11.2.3 Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Application (2020-2031)
- 11.3 Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country
- 11.3.1 Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 11.3.2 Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2020 VS 2024 VS 2031)
- 11.3.3 Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Country (2020-2031)
- 11.3.4 Japan
- 11.3.5 South Korea
- 11.3.6 India
- 11.3.7 Australia
- 11.3.8 Taiwan
- 11.3.9 Southeast Asia
- 12 South America, Middle East and Africa
- 12.1 SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Type
- 12.1.1 SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2020-2031)
- 12.1.2 SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2020-2031)
- 12.1.3 SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2020-2031)
- 12.2 SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Application
- 12.2.1 SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2020-2031)
- 12.2.2 SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2020-2031)
- 12.2.3 SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Application (2020-2031)
- 12.3 SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country
- 12.3.1 SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
- 12.3.2 SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2020 VS 2024 VS 2031)
- 12.3.3 SAMEA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Country (2020-2031)
- 12.3.4 Brazil
- 12.3.5 Argentina
- 12.3.6 Chile
- 12.3.7 Colombia
- 12.3.8 Peru
- 12.3.9 Saudi Arabia
- 12.3.10 Israel
- 12.3.11 UAE
- 12.3.12 Turkey
- 12.3.13 Iran
- 12.3.14 Egypt
- 13 Value Chain and Sales Channels Analysis
- 13.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Chain Analysis
- 13.1.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Raw Materials
- 13.1.2 Raw Materials Key Suppliers
- 13.1.3 Manufacturing Cost Structure
- 13.1.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Mode & Process
- 13.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Channels Analysis
- 13.2.1 Direct Comparison with Distribution Share
- 13.2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors
- 13.2.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers
- 14 Concluding Insights
- 15 Appendix
- 15.1 Reasons for Doing This Study
- 15.2 Research Methodology
- 15.3 Research Process
- 15.4 Authors List of This Report
- 15.5 Data Source
- 15.5.1 Secondary Sources
- 15.5.2 Primary Sources
- 15.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.